vs
AVADEL PHARMACEUTICALS PLC（AVDL）与STURM RUGER & CO INC（RGR）财务数据对比。点击上方公司名可切换其他公司
STURM RUGER & CO INC的季度营收约是AVADEL PHARMACEUTICALS PLC的2.0倍（$151.1M vs $77.5M），AVADEL PHARMACEUTICALS PLC同比增速更快（54.9% vs 3.6%），AVADEL PHARMACEUTICALS PLC自由现金流更多（$22.2M vs $12.3M），过去两年AVADEL PHARMACEUTICALS PLC的营收复合增速更高（99.6% vs 5.1%）
Avadel Pharmaceuticals是爱尔兰的专科制药企业，专注于睡眠障碍治疗药物的研发，产品覆盖医院及基层医疗场景，总部位于爱尔兰都柏林，在美国密苏里州圣路易斯、法国里昂均设有业务运营点。
鲁格公司（Ruger）是总部位于美国康涅狄格州绍斯波特的枪械制造企业，除总部外，还在新罕布什尔州纽波特、北卡罗来纳州梅约丹以及亚利桑那州普雷斯科特设有生产工厂。公司由亚历山大·麦考密克·斯特姆与威廉·B·鲁格于1949年共同创立，自1969年起公开上市交易。
AVDL vs RGR — 直观对比
营收规模更大
RGR
是对方的2.0倍
$77.5M
营收增速更快
AVDL
高出51.2%
3.6%
自由现金流更多
AVDL
多$9.9M
$12.3M
两年增速更快
AVDL
近两年复合增速
5.1%
损益表 — Q3 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $77.5M | $151.1M |
| 净利润 | $20.0K | — |
| 毛利率 | — | 17.8% |
| 营业利润率 | 2.5% | 2.3% |
| 净利率 | 0.0% | — |
| 营收同比 | 54.9% | 3.6% |
| 净利润同比 | 100.8% | — |
| 每股收益（稀释后） | $0.00 | $0.22 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收AVDLRGR
| Q4 25 | — | $151.1M | ||
| Q3 25 | $77.5M | $126.8M | ||
| Q2 25 | $68.1M | $132.5M | ||
| Q1 25 | $52.5M | $135.7M | ||
| Q4 24 | $50.4M | $145.8M | ||
| Q3 24 | $50.0M | $122.3M | ||
| Q2 24 | $41.5M | $130.8M | ||
| Q1 24 | $27.2M | $136.8M |
净利润AVDLRGR
| Q4 25 | — | — | ||
| Q3 25 | $20.0K | $1.6M | ||
| Q2 25 | $9.7M | $-17.2M | ||
| Q1 25 | $-4.9M | $7.8M | ||
| Q4 24 | $-5.0M | — | ||
| Q3 24 | $-2.6M | $4.7M | ||
| Q2 24 | $-13.8M | $8.3M | ||
| Q1 24 | $-27.3M | $7.1M |
毛利率AVDLRGR
| Q4 25 | — | 17.8% | ||
| Q3 25 | — | 15.1% | ||
| Q2 25 | 90.7% | 3.9% | ||
| Q1 25 | 89.4% | 22.0% | ||
| Q4 24 | 90.5% | 22.8% | ||
| Q3 24 | 87.7% | 18.5% | ||
| Q2 24 | 93.3% | 22.3% | ||
| Q1 24 | 94.4% | 21.5% |
营业利润率AVDLRGR
| Q4 25 | — | 2.3% | ||
| Q3 25 | 2.5% | -2.7% | ||
| Q2 25 | 13.0% | -15.6% | ||
| Q1 25 | -5.7% | 6.2% | ||
| Q4 24 | -6.5% | 7.8% | ||
| Q3 24 | -0.7% | 3.1% | ||
| Q2 24 | -30.7% | 6.9% | ||
| Q1 24 | -95.8% | 5.5% |
净利率AVDLRGR
| Q4 25 | — | — | ||
| Q3 25 | 0.0% | 1.2% | ||
| Q2 25 | 14.2% | -13.0% | ||
| Q1 25 | -9.4% | 5.7% | ||
| Q4 24 | -10.0% | — | ||
| Q3 24 | -5.2% | 3.9% | ||
| Q2 24 | -33.3% | 6.3% | ||
| Q1 24 | -100.6% | 5.2% |
每股收益（稀释后）AVDLRGR
| Q4 25 | — | $0.22 | ||
| Q3 25 | $0.00 | $0.10 | ||
| Q2 25 | $0.10 | $-1.05 | ||
| Q1 25 | $-0.05 | $0.46 | ||
| Q4 24 | $-0.04 | $0.62 | ||
| Q3 24 | $-0.03 | $0.28 | ||
| Q2 24 | $-0.14 | $0.47 | ||
| Q1 24 | $-0.30 | $0.40 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $91.6M | $92.5M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $98.2M | $283.8M |
| 总资产 | $199.4M | $342.0M |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资AVDLRGR
| Q4 25 | — | $92.5M | ||
| Q3 25 | $91.6M | $80.8M | ||
| Q2 25 | $81.5M | $101.4M | ||
| Q1 25 | $66.5M | $108.3M | ||
| Q4 24 | $73.8M | $105.5M | ||
| Q3 24 | $65.8M | $96.0M | ||
| Q2 24 | $71.4M | $105.6M | ||
| Q1 24 | $88.8M | $115.3M |
股东权益AVDLRGR
| Q4 25 | — | $283.8M | ||
| Q3 25 | $98.2M | $279.6M | ||
| Q2 25 | $90.7M | $289.3M | ||
| Q1 25 | $74.1M | $321.5M | ||
| Q4 24 | $73.8M | $319.6M | ||
| Q3 24 | $74.7M | $314.9M | ||
| Q2 24 | $70.3M | $321.5M | ||
| Q1 24 | $78.4M | $332.0M |
总资产AVDLRGR
| Q4 25 | — | $342.0M | ||
| Q3 25 | $199.4M | $342.3M | ||
| Q2 25 | $187.2M | $349.5M | ||
| Q1 25 | $167.9M | $379.0M | ||
| Q4 24 | $164.2M | $384.0M | ||
| Q3 24 | $158.3M | $373.5M | ||
| Q2 24 | $157.5M | $376.7M | ||
| Q1 24 | $167.9M | $385.0M |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $22.2M | $15.5M |
| 自由现金流经营现金流 - 资本支出 | $22.2M | $12.3M |
| 自由现金流率自由现金流/营收 | 28.7% | 8.2% |
| 资本支出强度资本支出/营收 | 0.0% | 2.1% |
| 现金转化率经营现金流/净利润 | 1110.25× | — |
| 过去12个月自由现金流最近4个季度 | — | $38.5M |
8季度趋势，按日历期对齐
经营现金流AVDLRGR
| Q4 25 | — | $15.5M | ||
| Q3 25 | $22.2M | $12.9M | ||
| Q2 25 | $12.7M | $14.7M | ||
| Q1 25 | $-8.2M | $11.1M | ||
| Q4 24 | $7.9M | $20.0M | ||
| Q3 24 | $-6.9M | $9.4M | ||
| Q2 24 | $-18.2M | $18.7M | ||
| Q1 24 | $-29.7M | $7.3M |
自由现金流AVDLRGR
| Q4 25 | — | $12.3M | ||
| Q3 25 | $22.2M | $7.0M | ||
| Q2 25 | — | $9.1M | ||
| Q1 25 | — | $10.0M | ||
| Q4 24 | — | $16.4M | ||
| Q3 24 | — | $2.6M | ||
| Q2 24 | — | $10.1M | ||
| Q1 24 | — | $5.6M |
自由现金流率AVDLRGR
| Q4 25 | — | 8.2% | ||
| Q3 25 | 28.7% | 5.5% | ||
| Q2 25 | — | 6.9% | ||
| Q1 25 | — | 7.4% | ||
| Q4 24 | — | 11.2% | ||
| Q3 24 | — | 2.1% | ||
| Q2 24 | — | 7.7% | ||
| Q1 24 | — | 4.1% |
资本支出强度AVDLRGR
| Q4 25 | — | 2.1% | ||
| Q3 25 | 0.0% | 4.6% | ||
| Q2 25 | — | 4.2% | ||
| Q1 25 | — | 0.8% | ||
| Q4 24 | — | 2.5% | ||
| Q3 24 | 0.0% | 5.5% | ||
| Q2 24 | — | 6.6% | ||
| Q1 24 | — | 1.3% |
现金转化率AVDLRGR
| Q4 25 | — | — | ||
| Q3 25 | 1110.25× | 8.15× | ||
| Q2 25 | 1.31× | — | ||
| Q1 25 | — | 1.43× | ||
| Q4 24 | — | — | ||
| Q3 24 | — | 1.98× | ||
| Q2 24 | — | 2.27× | ||
| Q1 24 | — | 1.04× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
AVDL
暂无分部数据
RGR
| Firearms | $150.6M | 100% |
| Castings | $7.3M | 5% |
